Business Trip tells the story of the emerging industry of psychedelics. Each episode features founders from biotech startups developing novel compounds, to clinics and retreats for healing, to software companies building tools to power the ecosystem.
Greg Kubin & Matias Serebrinsky
The Business Trip podcast is an incredibly insightful and informative show that delves into a variety of topics related to business and entrepreneurship. Hosted by Greg and Matias, this podcast offers valuable insights and perspectives from both their own experiences as well as from expert guests.
One of the best aspects of The Business Trip podcast is the wide range of topics covered. From marketing and sales strategies to leadership and personal development, there is something for everyone interested in the world of business. Greg and Matias do an excellent job of exploring these subjects in depth, providing practical advice and actionable tips that listeners can apply to their own lives and careers.
Another standout aspect of this podcast is the quality of the guests. Each episode features experts and industry leaders who offer unique insights into their respective fields. These guests provide valuable information and share their own experiences, adding depth and richness to each conversation. The hosts do a great job of asking thought-provoking questions that allow guests to share their expertise fully.
While The Business Trip podcast is overall a fantastic listen, one potential downside is that some episodes may not be relevant or interesting to all listeners. As with any podcast that covers a wide range of subjects, there may be certain episodes or discussions that do not resonate with everyone's specific interests or needs. However, given the diverse range of topics covered, it is likely that there will still be plenty of episodes that will captivate audiences.
In conclusion, The Business Trip podcast is an excellent resource for anyone looking to gain valuable insights into the world of business and entrepreneurship. With its diverse topics, knowledgeable hosts, and informative guests, this show offers inspiration, education, and new ways of thinking about opportunities in this ever-evolving field. Whether you are a seasoned entrepreneur or just starting out on your business journey, The Business Trip podcast is definitely worth a listen!
Greg and Matias interview Justin Mares, co-founder of TrueMed and Kettle & Fire on current US healthcare and how startups have the opportunity to change the system.In this episode, we discuss:How the US system profits from chronic illnessFixing the food system, environmental toxins, pharma incentives & moreOpportunities for founders building in brain and body health.Contrarian ideas Justin is investing in todayCredits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Caitlin Ner & Nico V. Rey Find us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
In this special episode of Business Trip, co-hosts Greg Kubin and Matias Serebrinsky sit down with Brooks Leitner, the newest partner at PsyMed Ventures, to explore the future of brain and mental health investing. Brooks, an MD/PhD with deep experience from Yale and the NIH, shares his insights on how a human-first approach is reshaping neuroscience innovation and venture investing. In this episode, we discuss:Broadening the Thesis: Evolving from a psychedelics-only focus to a comprehensive neuro investment strategy.Human-First Research: Shifting from animal models to clinical insights for better brain therapies.Key Investment Areas: Therapeutics, medical devices, diagnostics, consumer health, and AI-enabled care platforms.Early-Stage Conviction: Leveraging a prepared mind to spot breakthrough opportunities.Personal & Future Insights: Leadership challenges and the vision for the future of neuro investing.Credits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Greg and Matias interview Dr. Nir Grossman, one of the world's leading researchers in neurotechnology. Nir is a lecturer in the Department of Brain Sciences at Imperial College London and a founding fellow of the UK Dementia Research Institute. In this episode, we discuss:What is temporal interference (TI), a non-invasive stimulation methodA comparison of TI with deep brain stimulation (DBS)How physics plays a crucial role in neuroscience innovationTranslating TI academic research to clinical useTI's role in treating Alzheimer's, epilepsy, depression, and traumatic brain injuryCredits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Greg and Matias interview Dr. Jim Adams, professor and autism researcher at Arizona State University and President of Gut-Brain-Axis Therapeutics, on groundbreaking research in autism.In this episode, we discuss:The latest advancements in microbiome therapy for autismHow the gut-brain axis is shaping new therapeutic approachesThe role of nutritional interventions in supporting individuals with autismEnvironmental factors and toxins influencing autism developmentCredits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Matias interviews Elizabeth Horn, founder of the 2m Foundation, on the current state of autism and what can we do about it.In this episode, we discuss:The rising prevalence of autism and its impact on societyHow 2m Foundation is funding research and solutionsEnvironmental and biological factors contributing to autismPhilanthropy and venture capital through the Autism Impact FundCredits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Greg and Matias interview Dana Watt, a Partner at Breakout Ventures, about genetic medicine for brain and mental health.In this episode, we discuss:How genetic therapies work: addressing underlying causes, not just symptomsThe opportunities and challenges for genetic therapies for brain healthExploring effective delivery of genetic payloadsCommercial viability and insurance considerationsCredits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Greg and Matias interview Jay Sanguinetti, founder of Sanmai Technologies, a startup using transcranial focused ultrasound for the treatment of mental health conditions. Jay has a background in academia, having worked at the University of Arizona and started the SEMA Lab (Science Enhanced Mindful Awareness).In this episode, we discuss:The science behind transcranial focused ultrasound and its therapeutic potential for mental healthThe risks and considerations involved in using focused ultrasound technology for mental health treatmentsJay's experience transitioning from academia to founding a mental health technology startupThe regulatory landscape that Sanmai Technologies will navigate as they bring this novel neurotechnology to marketCredits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Greg and Matias interview Tim Marjenin, a regulatory consultant at MCRA with 16 years of experience at the FDA, to discuss the regulatory landscape for neurotechnology devices.Tim provides insights into the FDA approval process for neurotech devices, drawing from his extensive experience on the FDA's Neurostimulation-Neurology Devices Team. The episode explores the evolving field of neurotechnology and its regulatory challenges.In this episode, we discuss:Different regulatory pathways for neurological devices (510(k), De Novo, PMA)FDA's approach to novel neurotechnologies like brain-computer interfaces (BCIs)Considerations for invasive vs. non-invasive neurotech devicesThe importance of cybersecurity in neurotechnologyCommon mistakes companies make in the regulatory process and how to avoid themThe potential future of neurotechnology, including human augmentation and telepathyCreated by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank and Krotoa by Makropulos
Greg and Matias interview Gurdane Bhutani, an investor at MBX Ventures, to discuss the impact of environmental toxins on health and the field of exposomics.Gurdane is an expert in environmental health, with a background in Epidemiology and Environmental Health Sciences. He provided insights into the pervasive nature of environmental toxins and their implications for public health. This episode also has a guest appearance from Bruce Blumberg, a Professor of Developmental and Cell Biology at UC Davis.In this episode, we discuss:The widespread presence of environmental toxins and their link to diseases like Parkinson's and autismThe field of exposomics and lifetime environmental exposuresObesogens (chemicals whose exposure makes you fat)Startups building solutions for better diagnostics, green chemistry, and water treatmentPractical lifestyle changes to reduce exposure to harmful chemicals and improve healthCredits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank and Temperance by Eltham House
Greg and Matias interview Josh Hardman, founder and editor of Psychedelic Alpha, to discuss the recent FDA advisory committee meeting on Lykos Therapeutics' MDMA-assisted therapy for PTSD.Josh is a leading writer covering the intersection of psychedelics and business. He provided live reporting and analysis of the AdComm meeting.In this episode, we discuss:The FDA advisory committee process and its implications for drug approvalsFunctional unblinding and expectancy effects in psychedelic clinical trialsPotential impacts on the broader psychedelic medicine industryThe future of psychedelic-assisted psychotherapy protocolsNeuroplastogen development and non-hallucinogenic approachesChallenges around therapy, safety, and regulatory pathways for psychedelic medicinesCredits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Software, hardware, and biotechnology are playing an increasingly transformative role in our mental health and wellness. Join us as we discuss what investors look for in these new companies and how they separate what's real — and what's near-term — from what's hype. We'll explore AI-powered tools for mental health, the new area of “enerceuticals” (energy replacing the “pharma”), psychedelics, and why what's in your gut is so important to your mental state. Hear from investors who have a wide view of this growing startup landscape and better understand which new ventures are likely to succeed.This is a live panel from South by South West 2024 with panelists Matias Serebrinsky of PsyMed Ventures and Business Trip and Amy Kruse of Satori Capital, moderated by Christie Nicholson of Studio For Communicating Complexity and Dan Blumberg of Modern Product Minds and the CRAFTED. podcast.For more on CRAFTED., Dan's Webby-honored podcast featuring founders and leaders discussing what it really takes to build incredible products and companies, listen here: crafted.fm Credits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Matias hosted a panel at The Battery SF with renowned psychedelics experts, Nolan Williams, Allison Feduccia, Matt Baggott.Nolan is a Stanford professor currently researching ibogaine among other areas in psychiatry and radiology, and he's a founder of TMS company Magnus Medical. Allison is the founder of Psychedelic Support, a platform providing psychedelic education, community and a provider directory. And Matt is founder and CEO of Tactogen, a biotech company developing compounds similar to MDMA.In this episode, we discuss…The effects and mechanisms of different psychedelics (MDMA, psilocybin, ibogaine)The role of therapy/support during psychedelic experiencesScalability, accessibility, and optimal therapeutic useDigital solutions, new care models, and policy changes Credits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Matias interviews Lili Brillstein about how to work collaboratively with healthcare payers (the ones that reimburse for medical expenses).Lili is a pioneer in the field, having previously led one of the largest bundled payment initiatives at Horizon Blue Cross Blue Shield. She currently is the founder of her own advisory firm, BCollaborative, where she helps startups and providers develop value propositions that resonate with payers and create models that can be successfully administered. In this episode, they discuss:What payers want and their key prioritiesStrategies to communicate startup value propositions to payersThe role of interim successes for chronic conditionsHow to align payers, providers, and startupsFee-for-service vs. value-based care modelsCredits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Greg and Matias interview Ed Boyden about neuroscience frontiers and its applications to mental health.Ed is a pioneer in understanding the fundamental mechanisms of the brain. He runs a lab at MIT for Synthetic Neurobiology and is a professor across the departments of neurotechnology, biological engineering, and cognitive science at MIT's McGovern Institute for Brain Research. His inventions include optogenetic tools and expansion microscopy. He is co-founder of Cognito Therapeutics, Elemind, TI Solutions, and Synlife, and scientific advisor to several other companies. In this episode, we discuss…Academia vs. startups for neuroscience advancementEvaluating data vs intuition to assess new technologiesBreakthroughs like optogenetics and expansion microscopyHow to translate neurotech into companies/commercializationApproaches for clearly communicating and "storytelling" complex science.Credits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Greg and Matias interview Steve Rio about 5-MeO-DMT and its potential role in mental healthcare. Steve is a social impact cofounder, transformational coach, and practitioner at the Enfold Institute, one of the most reputable aboveground retreat centers working with 5-MeO-DMT. He shared many insights from his hands-on experience guiding hundreds of people through the medicine.In this episode, we discuss…5-MeO-DMT's distinct psychedelic experienceEnfold's protocol of screening, preparation and integrationWhy high doses may not fit into the mainstream medical model5-MeO's intense somatic release and non-dual experienceThe future of 5-MeO research and drug developmentMore information on Enfold Institute here: enfold.orgCredits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Tom Insel is an entrepreneur and former director of the US National Institute of Mental Health, the lead US agency supporting mental health research with a $2 billion budget. Since his time at the NIMH, Tom has built mental health technology, first at Verily and Mindstrong Health, and more recently founded Vanna Health, an online healthcare provider for serious mental illness.In his book "Healing", he talks about the importance of the 3 P's for solving the US mental health crisis: People, Place, and Purpose. Greg & Matias interview Tom on Business Trip to discuss the 4th "P": Payment. "We have to figure out how to pay for this", he says.In this episode, we discuss…Psychedelics in the healthcare systemAre antidepressants overprescribed? AI in mental healthTom's learnings from almost starting a VC fundCredits:Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
What if your next antidepressant was a clam or spinach?Greg & Matias invite Dr. Drew Ramsey to explore nutritional psychiatry - a field exploring how the food we eat can be as powerful as medication in treating mental illnesses like depression and anxiety.Dr. Drew Ramsey is a psychiatrist, entrepreneur and author focusing on nutritional interventions for mental wellbeing. Drew shares scientific research to make a business case for nutritional psychiatry - how customized food interventions could reduce healthcare costs for conditions like depression and anxiety. We debunk common myths around nutrition and mental health and envision a future where psychedelics and fermented foods may be first-line treatments. Ramsey offers simple diet tweaks you can make today for improved mental fitness.In this episode, we discuss…How nutritional psychiatry can be a cost-effective mental health treatmentWhy doctors need more nutritional education to prescribe food as medicine What startups and opportunities there are in this space What foods and nutrients are best for your mental healthTune into the episode to learn more!Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Can diet treat mental illness? Greg and Matias interview Jan Baszucki of the Baszucki Group whose son Matt overcame bipolar through the ketogenic diet.Jan has supported studies on ketogenic diets and fasting protocols for conditions like depression, schizophrenia, and bipolar disorder. In this episode we discuss:The powerful personal story behind Jan's passion for this fieldThe science and mechanistic details behind metabolic psychiatryMisconceptions about mental health and dietsChallenges to mainstream adoptionBusiness opportunities in metabolic interventionsThis is a must-listen for anyone interested in emerging non-pharmacological therapies for psychiatric disorders. Jan's perspective as an advocate, family member, philanthropist and impact investor provides a unique vantage point in this frontier space.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Advancements in neuroscience, AI, and bioengineering are unlocking new possibilities for neurotechnologies. Investors are paying attention.Alex Morgan of Khosla Ventures is an MD, PhD, physicist, and one of the most active investors in neurotech startups. He's backed companies harnessing neuromodulation for varied applications - from sleep (Somnee) to depression (Flow) to motor recovery (Syncron). In this episode, Alex shares an insider's overview of the neurotech landscape. We discuss when neurotech solutions make more sense than traditional pharma. Alex reveals which brain technologies excite him most, and why.We also unpack key business strategy questions. When should startups pursue the consumer route versus FDA approval? What does Alex look for in neurotech founders on the cutting edge?This episode is for founders, investors, clinicians, and researchers interested in understanding the cutting edge of neurotech and how it will become an integral part to the future of our mental health.
Neuromodulation flies in the face of modern psychiatry. It can significantly improve mental health without drugs. It allows us to stimulate or inhibit activity in precise regions of the brain using electricity, magnetism or ultrasound. Motif Neurotech is pioneering minimally invasive implants to precisely deliver neuromodulation for mental health. In this special episode, Matias joins Empath Ventures' Brom Rector to interview Jacob Robinson, an entrepreneurial scientist who leveraged his academic research to start Motif Neurotech. PsyMed Ventures and Empath Ventures invested in Motif's latest seed round. Motif's implantable device stimulates a region of the brain associated with depression. Other applications being explored include Alzheimer's disease, PTSD and ADHD.Neuromodulation is still early but holds great promise as a paradigm shift in psychiatry and even human augmentation–unlocking the full potential of the brain.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank and Temperance by Eltham House
In part 2 of a 2-part series, Greg and Matias explore microbial therapeutics for mental health with Dr. Christopher Reyes, biophysist, serial enterepreneur, and founder of Bloom Science. Dr. Reyes' research on leveraging microbes to treat neurological conditions began at UC San Francisco.He is now translating his microbiome research into startups targeting epilepsy, ALS, and even anxiety and depression. We discuss the science behind how gut microbes may influence neurotransmitters and mood. Dr. Reyes gives an insider perspective on the challenges of standardizing microbial therapies when each person has a unique microbiome fingerprint.We explore the regulatory landscape and future of microbial therapies for mental health. Dr. Reyes shares his experience navigating intellectual property, licensing deals, raising capital, and designing clinical trials to bring microbiome innovations to market. Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Business Trip launched in 2020 as a podcast focused on psychedelics. As Matias and Greg started to dive deeper into the complexities of mental health, they met more and more entrepreneurs and scientists creating novel treatments across many areas of mental health, including the gut microbiome.Dr. Phil Strandwitz pulls back the curtain on the gut-brain connection and the future of mental health. As founder of Holobiome, Phil is pioneering microbial therapies for conditions like depression and epilepsy.In part 1 of a 2-part series, we dive deep on how trillions of gut bacteria influence neurotransmitters, mood, cognition, and more. An imbalance in your microbiome could underlie mental health issues. Can fecal (poop) transplants treat depression? Phil shares how startups like Holobiome aim to develop microbiome-based treatments. We'll also explore lifestyle changes like diet, prebiotics, and probiotics to support gut health.Part frontier medicine, part taboo, this conversation will change how you think about the gut-brain connection. Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Stanford University is one of the leading universities in psychedelic science, focusing on understanding how psychedelics work in the body. This is part 3 of a 3-part series, where we will explore groundbreaking discoveries via leading Stanford researchers who are revealing the significance of psychedelic science in modern research. We conclude the series with Carolyn Rodriguez.Carolyn Rodriguez is Associate Dean at Stanford University School of Medicine and a psychiatrist at the Palo Alto VA. As Director of the Rodriguez Translational Therapeutics Lab, she leads studies on severe mental illness. Her clinical trials pioneer rapid-acting treatments for OCD and related disorders demonstrating ketamine's efficacy in reducing OCD symptoms. She now plans placebo-controlled studies of MDMA and other psychedelics, unlocking their therapeutic potential for OCD.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Stanford University is one of the leading universities in psychedelic science, focusing on understanding how psychedelics work in the body. This is part 2 of a 3-part series, where we will explore groundbreaking discoveries via leading Stanford researchers who are revealing the significance of psychedelic science in modern research. We continue with Boris Heifets.Boris Heifets, an assistant professor at Stanford's School of Medicine. Boris leads the Heifets Lab, which is dedicated to understanding and improving on powerful, rapid-acting therapies for psychiatric disease, such as ketamine, MDMA and psilocybin. Boris is an anesthesiologist and neurologist, a combination that uniquely positions him to design a research study evaluating the effect of ketamine on patients under anesthesia with depression. Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Psychedelics have long been known to induce altered states of consciousness. But there are many other techniques that can also expand our awareness - from meditation and breathwork to exploring dreams, prayer, light and sound. In this episode, Greg speaks with Scott Britton about the emerging startup landscape around tools for expanding consciousness.Scott is an entrepreneur who now writes a newsletter called Consciousness ∞ The Doorway to Human Evolution He also hosts a podcast called EvolutionFM.This special episode is a deeper dive into Greg & Scott's recent article about the consciousness startup ecosystem.In this episode, we discuss:VC-backable business models in psychedelic medicineHardware devices that induce deeper meditation and lucid dream statesBreathwork: app vs. in-person experiences Prayer apps attracting huge investmentStartups using sound, light, and visuals to catalyze altered statesIntegrating ancient wisdom into modern consciousness-expanding techCredits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Stanford University is one of the leading universities in psychedelic science, focusing on understanding how psychedelics work in the body. In this 3-part series, we will explore groundbreaking discoveries via leading Stanford researchers who are revealing the significance of psychedelic science in modern research. We start the series with Robert Malenka.Robert Malenka is a professor of psychiatry at Stanford University with over three decades of experience in preclinical neuroscience research. His primary focus is on the study of psychoactive drugs, including psychedelics, and their potential therapeutic applications. In addition to his academic role, Malenka is a founder and deputy director of the Wsai Neurosciences Institute at Stanford.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Psychedelic Science 2023, Learning Man, MAPS Burn...whatever you want to call it...was a magical conference organized by MAPS.12k people made the pilgrimage to Denver to discuss psychedelic science, culture, business, art, spirituality, and more.Rick Doblin called this the "Psychedelic 20's" and this event felt like a watershed moment.Luckily, Greg brought his microphone and recorded his experience for a special episode of Business Trip.Guests include Zach Haigney, Myriam Barthes, Lauren Taus, Hamilton Morris, and many more…Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
What does it take for a traditional VC to fund a psychedelic company? In our latest episode, Matias takes us behind the scenes of a panel discussion at the Psychedelic Therapeutics & Drug Development Conference in San Francisco, CA. Matias talks with VCs at firms with $100M+ fund sizes: Anne Dwane, a partner at Village Global, Amanda Way, principal at Jazz Venture Partners and Dana Watt PhD, principal at Breakout Ventures.In this episode, we discuss: (1) How VCs identify and evaluate a strong founding team, (2) Evaluating scientific, technical, and market risk, (3) The pros and cons of platforms vs. asset companies, (4) How to position a psychedelic company in the broader biotech ecosystem.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
In our latest episode, Greg and Matias engage in an insightful discussion with Dr. Bryan Roth, the Michael Hooker Distinguished Professor of Pharmacology at the University of North Carolina Chapel Hill School of Medicine, and the founder of the Roth Lab.Dr. Roth's lab is on the cutting edge of researching the interaction between brain cell receptors and compounds like LSD and psilocybin. Their findings have the potential to revolutionize the treatment of psychiatric disorders, potentially creating new forms of psychedelics that offer the therapeutic benefits without hallucinations or other side effects.In this episode, we discuss (1) the therapeutic effects of psychedelic and non-hallucinatory compounds, (2) the transition from animal model studies to human trials and (3) the journey of turning deep academic research into viable commercial entities.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
In this week's episode, Greg and Matias take a moment to reflect on the opportunities and challenges they have faced while building the PsyMed Ventures syndicate and venture capital fund since starting the Business Trip podcast in 2020. Their ultimate goal is to support founders who are building ethical businesses in frontier mental health technologies with the aim of ending the suffering caused by mental illnesses. This conversation offers an honest insight into raising and deploying a venture capital fund as an emerging manager. Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Nico V. Rey & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
In this week's episode, Greg and Matias chat with Josh Hardman, the founder of Psychedelic Alpha. Josh is a leading writer and founder at Psychedelic Alpha, an online resource, newsletter, and community covering the intersection of psychedelics and business. He regularly collaborates and writes with experts in the psychedelic field including entrepreneurs, academic researchers, non-profits, and more to provide a comprehensive understanding of the latest developments in the industry. Psychedelic Alpha recently released Psychedelics 2022: A Year in Review to comment on and analyze the industry across research, funding, and policy.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Zack Frank, & Caitlin NerFind us at businesstrip.fm and psymed.venturesFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
In this week's special episode, Matias chats with Dr. Rachel Yehuda and Zach Haigney at Soho House in New York City. This is part 2 of a moderated panel recorded in front of a live audience, with part 1 released in June 2022. Dr. Yehuda has spent the last 30 years doing research on PTSD and trauma and is leading the MDMA-assisted therapy research at the US Veterans Affairs Medical Center and serves as Director at the Mental Health at the James J. Peters VA Medical Center. She is also the Director of the Center for Psychedelic Psychotherapy and Trauma Research at the Icahn School of Medicine at Mount Sinai Hospital and Professor of Psychiatry and Neuroscience. Zach Haigney writes the Trip Report by Beckley Waves, a newsletter about the science, policy, and business of psychedelics.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis, Zack Frank, & Caitlin NerFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
This episode shares the story of Tactogen, a drug development company making new chemical entities inspired by MDMA. Co-founder Matt Baggott has been fascinated by MDMA and has studied it for 30 years. And while he believes that MDMA can be effective as a therapeutic, his company is developing an MDMA analogue that is designed to be gentler and safer, with the potential to be administered in an at-home setting. Links:Tactogen WeFunder: https://wefunder.com/tactogenCredits: Created by Greg Kubin and Matias SerebrinskyHost: Matias SerebrinskyProduced by Jonathan A. Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music:Distant Daze by Zack Frank
In this new episode of Business Trip, we interview one of the first clinics to offer a protocol that includes TMS (transcranial magnetic stimulation) and ketamine infusion.TMS is a non-invasive procedure that sends electric currents to specific regions in the brain, including areas linked to depression. It's FDA approved and has been gaining adoption as clinical studies demonstrate safety and efficacy in treating mood disorders.So why the combination? TMS takes a local approach while ketamine stimulates global brain communication, according to Scenic City Neurotherapy founder Charles Miller. There's little data about the combination of TMS with ketamine, making this conversation quite interesting as Miller shares the protocol, science, costs, and treatment outcomes.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias SerebrinskyProduced by Jonathan Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music:Distant Daze by Zack Frank
In this week's episode, we chat with Christian Angermayer. Christian co-founded atai Life Sciences and was an early investor in Compass Pathways -- two of the first companies commercializing psychedelic medicine. Christian also launched a fund dedicated to mental and neurological health called re:Mind, is an investor through his family office Apeiron, and co-founded two longevity biotech companies.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Greg Kubin and Matias SerebrinskyProduced by Jonathan Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music:Distant Daze by Zack Frank
In this week's episode, we chat with Melissa Stangl, co-founder of Soltara Healing Center. Soltara is an ayahuasca retreat center whose ceremonies are lead by Shipibo healers, with locations in Peru and Costa Rica. The Shipibo people are from the Peruvian Amazon and are part of a tradition that has been drinking Ayahuasca for healing and spiritual purposes for thousands of years. In their ceremonies, the Shipibo serve ayahuasca and sing songs, called Icaros, which guide the healing process and journey.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Greg Kubin and Matias SerebrinskyProduced by Jonathan Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music:Distant Daze by Zack Frank
This is final episode in our 3-part series on microdosing that explores the science, history, and clinical applications. In this episode, we discuss the path to FDA approval for microdosing. We chat with the chief medical officers from Diamond Therapeutics and MindMed about their microdosing clinical programs. Diamond's program uses synthetic psilocybin and is focused on anxiety disorders. Meanwhile, MindMed is focused using low doses of LSD to treat adult ADHD. Our guests are Dr. Michael McDonnell (Diamond Therapeutics) and Dr. Dan Karlin (MindMed).In case you missed it: In part 1, we interviewed psychedelic researcher James Fadiman about the fundamentals of microdosing. In part 2, we discuss placebo effect and the results of a self-blinded placebo-controlled study with Balázs Szigeti from the Centre for Psychedelic Research at Imperial College London.Disclaimer: This is not investment advice and is for information and educational purposes only. Credits: Created by Greg Kubin and Matias SerebrinskyHost: Greg Kubin and Matias SerebrinskyProduced by Jonathan Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music:Distant Daze by Zack Frank
This is part 2 or our 3 part series on microdosing that explore the science, history, and clinical applications. In part 1, we interviewed psychedelic researcher James Fadiman about the fundamentals of microdosing. In part 2, we wanted to understand the placebo effect. In particular, is it the microdose that makes people feel better or it is a placebo effect? We interviewed Balázs Szigeti PhD, who is a researcher associate at the Centre for Psychedelic Research at Imperial College London. His team conducted the largest placebo-controlled microdosing study in 2020. Balázs unpacks the study and their findings in the episode.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Greg Kubin and Matias SerebrinskyProduced by Jonathan Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack FrankZone Out by Daniel FridellLinks to topics discussed in this episode:Self-blinding citizen science to explore psychedelic microdosing (Szigeti et al., 2021)Centre for Psychedelic Research - Imperial College LondonStatistical and clinical significance
In this 3-part series on microdosing, we explore the science, history, and its clinical potential. The anecdotal benefits of microdosing include better mood, creativity, and increased focus. But there are still many unanswered questions that remain. What is an effective dosing protocol? Is it safe in long term use? Does it even work or is it a placebo effect?In part 1, we chat with James Fadiman, Ph.D who has been researching psychedelics since the 1960's. He's the author of several books, including the Psychedelic Explorer's Guide. He has collected thousands of microdosing reports and even has his own microdosing protocol - called the Fadiman protocol. When we talk about standing on the shoulders of giants, James Fadiman is one of them.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Greg Kubin Produced by Jonathan Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack FrankLinks to topics discussed in this episode:Jim's microdosing websiteSofia UniversityThe Psychedelic Explorer's GuidePsychedelics Promote Structural and Functional Neural Plasticity (Ly et al, 2018)
In this week's episode, we chat with Matt Zorn, an attorney at Yetter Coleman with expertise in DEA law, especially regarding psychedelics. Matt is currently challenging the DEA's decision to schedule 5 new tryptamines, he recently argued Kathryn Tucker's psilocybin “Right To Try” case against the DEA, and previously co-led Sue Sisley's DEA case related to cannabis scheduling. Matt also writes the drug policy newsletter On Drugs.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
In this week's special episode, Matias chats with Dr. Rachel Yehuda and Zach Haigney at Soho House in New York City. The episode was recorded in front of a live audience. Dr. Yehuda has spent the last 30 years doing research on PTSD and trauma and is leading the MDMA-assisted therapy research at the US Veterans Affairs Medical Center. She is the Director at the Mental Health Patient Care Center at the James J. Peters VA Medical Center, Director of the Center for Psychedelic Psychotherapy and Trauma Research at Mount Sinai Hospital, as well as Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai Hospital. Zach Haigney writes the Trip Report by Beckley Waves, a newsletter about the science, policy, and business of psychedelics.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
In Episode 18, we chat with Jonathan Sabbagh and Myriam Barthes, the co-founders of Journey Clinical, a platform that enables licensed therapists to offer ketamine-assisted psychotherapy (KAP). Journey Clinical provides licensed therapists with an on-demand KAP-trained medical team, customized treatments for each client, and a portal to connect with other therapists and educational resources.In this episode, we discuss:The journey from idea to 100+ therapist membersHow ketamine-assisted therapy works and the Journey Clinical's vision for the futureBalancing growth with protecting the relationship between patient and therapistCredits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
In today's episode, we chat with Lucia Huang, the CEO and co-founder of Osmind, an electronic health record software system for treatment resistant mental health practices that is already in over 300 clinics. In this episode, we discuss:How Osmind makes data-driven decisions Osmind's quick growth in only 2 yearsWhat it will take for insurance to cover ketamine therapy, as well as other psychedelic therapiesCreated by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
In today's episode, we chat with Tim Schlidt, a partner at Palo Santo. Palo Santo is a $35M fund investing in psychedelic therapeutics. Palo Santo's portfolio includes companies like Eleusis, Tactogen, and Journey Clinical.In this episode, we discuss:Tim's background in healthcare financeInvesting in classic psychedelic compounds vs. 2nd generation compoundsHallmarks of a good first meeting with a prospective investmentCreated by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank
Today's episode features Dillan Dinardo and Tom Ray, the co-founders of Mindstate Design Labs. Mindstate has a unique framework to design psychedelic compounds using what they call the “primer probe method.” This method involves combining a known psychedelic with a non-psychedelic compound. Mindstate just raised an $11.5M seed round.In this episode, we discuss:Tom and Dillan's experience in YCombinator and raising an $11.5M seed roundTom's friendship with the late psychedelic chemist Alexander ShulginMindstate's lead programsThe role of mystical states in the healing processCreated by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian Love
Today's episode announces the launch of PsyMed Ventures, a $25M fund we started with Dina Burkitbayeva to invest in psychedelic medicine companies and mental health technologies. PsyMed Ventures is a community-focused fund and syndicate providing capital and support to companies revolutionizing how mental health is treated.In this episode, we discuss:$25M fund to invest in psychedelic medicine companies and mental health techHow we evaluate new companiesExciting trends in mental health researchOur story from starting Business Trip to launching an investment syndicate and fundCreated by Greg Kubin and Matias SerebrinskyHost: Greg KubinProduced by Jonathan Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian Love
Today's episode features Amy Emerson, the CEO of MAPS Public Benefit Corporation (PBC), which is a fully owned subsidiary of MAPS, and its purpose is to commercialize MDMA-assisted therapy. We discuss the MAPS PBC and it's business model for MDMA-assisted therapy.In this episode, we discuss:MAPS' protocol and strategy behind FDA clinical trial for PTSDAmy's views on the state of the industry, patents, and how to prioritize accessibilityThe unique business model between MAPS and MAPS PBCPsychedelics for kidsCreated by Greg Kubin and Matias SerebrinskyHost: Greg Kubin and Matias SerebrinskyProduced by Jonathan Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music: Focus Does the Girl by Muted Circus
In today's episode, we discuss what it's like being a psychologist who owns a psychedelic clinic. Genesee Herzberg is the co-founder of Sage Integrative Health, an integrative clinic in Berkeley, CA that offers ketamine-assisted therapy (KAP), psychotherapy, somatic therapy, and acupuncture. Genesee discusses her holistic approach to healing, and shares her experience bootstrapping her clinic and setting up a non-profit to make KAP more affordable.In this episode, we discuss:Ketamine-assisted psychotherapy and the difference between high and low dose ketamine treatmentsWhat it takes to get a for-profit clinic off the ground while running a non-profit organizationSage Institute's mission to make ketamine-assisted psychotherapy affordable for everyoneGenesee's long term goals for the future of psychedelic medicineCreated by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan Davis & Zack FrankMarketing by DaisyMae VanValkenburghRead the transcript here.Find us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music: Flocean by Zack Frank
In today's episode, we explore the therapeutic application of DMT across a range of diseases and conditions including Alzheimer's, stroke, and organ transplants. While much of the attention in psychedelic medicine has been on their ability to address neuropsychiatric indications, research suggests that psychedelics like DMT have a far wider therapeutic potential. The episode features three biotech companies developing DMT therapies: Algernon, Psilera, and Pharmadrug.In this episode, we discuss:DMT therapies for organ transplants, stroke patients and substance abuse disordersResearch supporting NN-DMT's antioxidative and anti-inflammatory effects and the receptors it targetsBeing a private company vs. public company in psychedelicsNN-DMT5-MeO-DMTBioavailabilityDMT transdermal patchSigma-1DonepezilDr. Rick StrassmanAngiogenesisOrphan Drug DesignationCreated by Greg Kubin and Matias SerebrinskyHost: Matias SerebrinskyProduced by Jonathan Davis & Zack FrankMarketing by DaisyMae VanValkenburghRead the transcript here.Find us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music: Copley Beat by Blue Dot Sessions, Simplify by Little Glass Men, Pedalrider by Blue Dot Sessions, Running Waters by Jason Shaw, and Neon Drip by Blue Dot Sessions
Episode 10 features Lars Wilde, co-founder and Chief Business Officer of Compass Pathways, a mental health company with an initial focus on psilocybin therapy for Treatment-Resistant Depression.In this episode, we discuss:Lars' experience overcoming Treatment-Resistant Depression with psilocybinThe nuances of clinical trials and psilocybin dosing protocolsCompass Pathways' Intellectual Property strategyWhat additional indications and therapies Compass Pathways is interested inLinks to topics discussed in this episode:Compass Pathways, Lars WildeCOMP360SSRI, SNRIChristian Angermayer, Robin Carhart-Harris, Michael PollanVivaneoQuercis PharmaTRD (Therapy-Resistant Depression)Compass Phase 2B TrialJazz PharmaceuticalsCompass Pathways 2 US patentsOregon Psilocybin Therapy Measure 109Read the transcript here.Watch episode 10 on YouTube.Created by Greg Kubin and Matias SerebrinskyHosts: Matias Serebrinsky and Greg KubinProduced by Jonathan Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music: River Meditation by Jason Shaw and Thea by Muted Circus
Today's episode features three experts, Josh Hardman, Michael Haichin, and Graham Pechenik as they analyze atai's S-1 in advance of their IPO. In this episode, we discuss:How atai went from idea to IPO in 3 yearsAn overview of atai's drug development programs and enabling technologiesThe platform's strategy and risksLinks to topics in this episode:Atai life sciencesEtifoxineEsketamine & arketamineAtai's S-1Psychedelic Pharmacist AssociationCalyx LawPsilocybin Alpha, Noetic Fundkratom, Salvinorin A, BNC210, mitragynineMike Novogratz, Christian Angermayer, George Goldsmith, Ekaterina Malievskaia, Peter ThielPureTech Health, Akili Interactive LabsBT's DemeRx EpisodeViridia Life Sciences, EmpathBio, Kures, Recognify Life SciencesRead the transcript here.Watch episode 9 on YouTube.Created by Greg Kubin and Matias SerebrinskyHost: Matias SerebrinskyProduced by Jonathan Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music: The Innovation by Zack Frank (our very own sound engineer
© 2020-2025 Ivy Podcast Discovery LLC
